Shots:
The P-IIa trial evaluates URO-902 (24/48mg) vs PBO in 80 female patients with OAB who have not been adequately managed with oral or transdermal pharmacologic therapy
The results showed that patients treated with URO-902 at both doses showed clinically relevant improvement in mean daily urination, urgency episodes, UUI episodes, OAB questionnaire symptom bother score & global impression of change responders @12wk., TEAEs (45.5%/46.2% vs 50.0%), 1 patient in 48mg dose had asymptomatic elevated post-void residual urine volume @2wk.
In prespecified 12wk. analysis, patients showed a clinically relevant improvement in efficacy & was well tolerated in women with OAB & UUI who have failed oral therapies
Ref: Urovant | Image: Urovant Sciences
